QuidelOrtho (NASDAQ:QDEL) Releases Earnings Results, Beats Expectations By $0.18 EPS

QuidelOrtho (NASDAQ:QDEL) announced its earnings results on Thursday. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.18, FiscalAI reports. The company had revenue of $630.90 million during the quarter, compared to analysts’ expectations of $618.72 million. QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. QuidelOrtho updated its FY 2026 guidance to 0.650-0.900 EPS.

QuidelOrtho Price Performance

QDEL traded down $1.18 during trading on Thursday, hitting $16.32. 2,724,490 shares of the stock traded hands, compared to its average volume of 1,756,368. The business has a 50 day moving average price of $15.70 and a 200 day moving average price of $17.70. The company has a debt-to-equity ratio of 1.33, a current ratio of 1.43 and a quick ratio of 0.80. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -0.92 and a beta of 0.68.

Institutional Trading of QuidelOrtho

Institutional investors and hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. grew its position in QuidelOrtho by 7.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock valued at $337,925,000 after acquiring an additional 819,908 shares during the last quarter. Invesco Ltd. increased its position in QuidelOrtho by 19.4% during the 4th quarter. Invesco Ltd. now owns 3,470,656 shares of the company’s stock worth $99,122,000 after purchasing an additional 563,893 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in QuidelOrtho by 14.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,859,455 shares of the company’s stock valued at $84,208,000 after purchasing an additional 350,636 shares during the last quarter. State Street Corp boosted its position in QuidelOrtho by 1.3% in the fourth quarter. State Street Corp now owns 2,704,355 shares of the company’s stock valued at $77,236,000 after buying an additional 35,616 shares in the last quarter. Finally, Newtyn Management LLC boosted its position in QuidelOrtho by 58.3% in the third quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock valued at $79,515,000 after buying an additional 994,332 shares in the last quarter. 99.00% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on QDEL. UBS Group reaffirmed a “neutral” rating and set a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Zacks Research raised shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a report on Friday, July 17th. Citigroup lifted their price target on shares of QuidelOrtho from $13.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, JPMorgan Chase & Co. boosted their price target on QuidelOrtho from $11.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, July 1st. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and a consensus price target of $13.62.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.